Article

Sponsored Content

Format Follows Function: Media Considerations for Future-Proofing AAV Manufacturing Processes

Author(s):

Thermo Fisher Scientific

Although the potential of gene therapy has been established for decades, it is only in recent years that the industry has seen a major turning point with the first therapies receiving approval in the late 2010s. As the potential of these therapies is realized, the question of the hour is: how do we manufacture AAV gene therapies sustainably in the long term?

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Content
Site Logo
July 31st 2025

The Roadmap to Asset Performance Management in Life Science

BlueMountain
Site Logo
July 31st 2025

Unlock the Future of Enterprise Asset Management with Agentic AI

BlueMountain
Site Logo
July 31st 2025

From Maintenance to Compliance: A Guide to CMMS/EAM Readiness

BlueMountain
Site Logo
July 31st 2025

Executive Summary: End-To-End Regulatory CDMO Solutions: Development, Manufacturing, and Approval

Lonza
The road to market access is long and complex. Choosing a CDMO with experienced staff can prove vital to success. In this executive summary, Praveenkumar Devakadaksham and Dr. Roché Marcel Walliser explain all the ways they help make the journey from pharmaceutical development to commercial distribution as smooth as possible. Learn more about:
Site Logo
July 31st 2025

Executive Summary: Keys to Supplying Decentralized Trials: The Value of Direct-to-Patient Solutions and the Pharmacy-Led Model

Catalent
Site Logo
July 31st 2025

Innovations in Pregastric Absorption Drug Delivery & Orally Disintegrating Tablets

Catalent